Thermo Fisher Scientific Announces Collaboration to Advance Biopharmaceutical Characterization and Monitoring Methods

SUNNYVALE, Calif., April 8, 2019 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and Genovis, a leading provider of enzyme products for biological drug development, begin a collaborative research project to develop advanced end-to-end workflows for the preparation, characterization and monitoring of novel and complex biotherapeutics using liquid chromatography-mass spectrometry (LC-MS).

Bringing together Thermo Fisher’s leading LC-MS technology with the advanced enzyme-based sample preparation and analysis techniques of Genovis will enable the development of robust, automation-ready, magnetic bead and chromatography-based workflows for the streamlined analysis of biotherapeutics. Expertise from Thermo Fisher’s Global Customer Solution Centers will also help Genovis to determine optimal hardware/software configurations and suitable consumables for critical quality attribute (CQA) analysis of biotherapeutics during the research and development phase.

“With the shift toward large biological entities, companies are aiming to bring to market medicines with greater affinity and efficacy, but these medicines also present an additional level of analytical complexity,” said John Rontree, senior director, global marketing and strategy, pharmaceuticals and biopharmaceuticals, Thermo Fisher Scientific. “By collaborating with Genovis, we plan to develop comprehensive workflows that provide robust and advanced solutions for preparing and assessing complex biotherapeutics.”

“We are excited to work with Thermo Fisher Scientific to continue our goal toward more automated analytical workflows,” said Fredrick Olsson, chief executive officer at Genovis. “Through this collaboration we will be able to develop new products and workflows on world-class instrumentation together with experts from Thermo Fisher’s European Biopharma Customer Solution Center and serve the growing analytical needs of biopharma customers of both companies with meaningful innovations.”

The combination of the Thermo Scientific Vanquish Duo UHPLC Systems (with Dual LC workflow) and the Thermo Scientific Chromeleon Chromatography Data System (CDS) Software with the SmartEnzyme technology from Genovis will enable the development of LC-MS-based protocols for O-glycosylation profiling and automated high-throughput workflows for critical quality attribute (CQA) analysis of monoclonal antibodies at the subunit level.

For more information about Thermo Fisher’s chromatography and mass spectrometry workflows for biopharmaceutical characterization, please visit www.thermofisher.com/contactmebiopharma.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

Media Contact Information:

Laura Bright
Thermo Fisher Scientific
+1 562-335-8318           
laura.bright@thermofisher.com

Ronan Muir
BioStrata
+44 (0) 1223 627133
rmuir@biostratamarketing.com

SOURCE Thermo Fisher Scientific